Is Axsome Therapeutics Stock a Good Investment?
Axsome Therapeutics Investment Advice | AXSM |
- Examine Axsome Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Axsome Therapeutics' leadership team and their track record. Good management can help Axsome Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Axsome Therapeutics' business and its evolving consumer preferences.
- Compare Axsome Therapeutics' performance and market position to its competitors. Analyze how Axsome Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Axsome Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Axsome Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Axsome Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Axsome Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Axsome Therapeutics Stock
Researching Axsome Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 5.77. Axsome Therapeutics had not issued any dividends in recent years.
To determine if Axsome Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Axsome Therapeutics' research are outlined below:
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 395.36 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat |
Axsome Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Axsome Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Axsome Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2016-05-11 | 2016-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2017-08-09 | 2017-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2017-11-08 | 2017-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.41 | -0.08 | 24 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2018-05-08 | 2018-03-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2021-08-09 | 2021-06-30 | -0.96 | -0.86 | 0.1 | 10 |
Axsome Therapeutics Target Price Consensus
Axsome target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Axsome Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 19 | Strong Buy |
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Axsome Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAxsome Therapeutics Target Price Projection
Axsome Therapeutics' current and average target prices are 105.44 and 178.10, respectively. The current price of Axsome Therapeutics is the price at which Axsome Therapeutics is currently trading. On the other hand, Axsome Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Axsome Therapeutics Market Quote on 3rd of July 2025
Target Price
Analyst Consensus On Axsome Therapeutics Target Price
Axsome Therapeutics Analyst Ratings
Axsome Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Axsome Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Axsome Therapeutics' financials, market performance, and future outlook by experienced professionals. Axsome Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Axsome Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Axsome Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Therapeutics backward and forwards among themselves. Axsome Therapeutics' institutional investor refers to the entity that pools money to purchase Axsome Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2025-03-31 | 703.3 K | Alethea Capital Management, Llc | 2025-03-31 | 667.4 K | Assenagon Asset Management Sa | 2025-03-31 | 627.4 K | Partner Fund Management Lp | 2025-03-31 | 556.5 K | D. E. Shaw & Co Lp | 2025-03-31 | 547.7 K | Bank Of America Corp | 2025-03-31 | 533.9 K | Man Group Plc | 2025-03-31 | 513.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 457.4 K | Nuveen, Llc | 2025-03-31 | 413.1 K | Vanguard Group Inc | 2025-03-31 | 3.9 M | Blackrock Inc | 2025-03-31 | 3.5 M |
Axsome Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.12 B.Axsome Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (0.64) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.46.Determining Axsome Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Axsome Therapeutics is a good buy. For example, gross profit margin measures Axsome Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Axsome Therapeutics' profitability and make more informed investment decisions.
Evaluate Axsome Therapeutics' management efficiency
Axsome Therapeutics has return on total asset (ROA) of (0.2617) % which means that it has lost $0.2617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8216) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year.Leadership at Axsome Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.469 |
Basic technical analysis of Axsome Stock
As of the 3rd of July, Axsome Therapeutics shows the Risk Adjusted Performance of (0.12), standard deviation of 2.31, and Mean Deviation of 1.73. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics information ratio and skewness to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 105.44 per share. Given that Axsome Therapeutics has information ratio of (0.12), we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Axsome Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Axsome Therapeutics' Outstanding Corporate Bonds
Axsome Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axsome Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axsome bonds can be classified according to their maturity, which is the date when Axsome Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AYDEMT 775 02 FEB 27 Corp BondUS054644AA72 | View |
Understand Axsome Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Axsome Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 1.73 | |||
| Coefficient Of Variation | (1,335) | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.32 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 10.14 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 3.42 | |||
| Skewness | (0.58) | |||
| Kurtosis | 2.03 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 1.73 | |||
| Coefficient Of Variation | (1,335) | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.32 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 10.14 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 3.42 | |||
| Skewness | (0.58) | |||
| Kurtosis | 2.03 |
Consider Axsome Therapeutics' intraday indicators
Axsome Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Axsome Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Axsome Therapeutics time-series forecasting models is one of many Axsome Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Axsome Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Axsome Stock media impact
There is far too much social signal, news, headlines, and media speculation about Axsome Therapeutics that are available to investors today. This information is accessible both publicly - through Axsome Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Axsome-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Axsome Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Axsome Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Axsome Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Axsome Therapeutics alpha.
Axsome Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Axsome Therapeutics Historical Investor Sentiment
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Axsome Therapeutics.
Axsome Therapeutics Maximum Pain Price Across September 19th 2025 Option Contracts
Axsome Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Axsome Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Axsome Therapeutics' options.
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Already Invested in Axsome Therapeutics?
The danger of trading Axsome Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Axsome Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Axsome Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Axsome Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.77) | Revenue Per Share 8.95 | Quarterly Revenue Growth 0.62 | Return On Assets (0.26) | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Axsome Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.